共 71 条
[1]
Curigliano G(2017)De-escalating and escalating treatments for early-stage breast cancer the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Ann Oncol 28 1700-1712
[2]
Burstein HJ(2007)Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer Cancer 110 244-254
[3]
Winer EP(2004)Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1 Mol Endocrinol 18 402-411
[4]
Semiglazov VFSV(2002)Endocrine-responsive breast cancer and strategies for combating resistance Nat Rev Cancer 2 101-112
[5]
Dashyan GA(2005)International expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 1569-1583
[6]
Wang DYFR(1989)Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens J Clin Oncol 7 710-717
[7]
Liss SN(1985)Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro J Clin Oncol 3 1672-1677
[8]
Edwards EA(2007)Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells Cancer Chemother Pharamcol 59 515-525
[9]
Ali SCR(2011)Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial J Natl Can Inst 103 1529-1539
[10]
Goldhirsch A(2009)A randomized trial of adjuvant chemotherapy and tamoxifen timing in postmenopausal, endocrine-responsive, node-positive breast cancer Lancet 374 2055-2063